Pharmacological treatment of bereavement-related distress: a systematic review.
9 affiliations
- 1Weill Cornell Medical College, New York, NY, USA.
- 2Cornell Center for Research on End-of-Life Care, New York, NY, USA.
- 3Department of Psychiatry & Behavioral Health, Stony Brook Medicine, Stony Brook, NY, USA.
- 4Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
- 5Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
- 6Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medicine, New York, NY, USA.
- 7Department of Sociology, Appalachian State University, Boone, NC, 28608, USA.
- 8ARQ Centrum'45/ ARQ National Psychotrauma Center, Diemen, The Netherlands.
- 9University of Humanistic Studies, Utrecht, The Netherlands.
Abstract
Background: With the recent addition of prolonged grief disorder into diagnostic manuals both in the United States (i.e. DSM-5-TR) and internationally (i.e. ICD-11), interest in pharmacologic treatment for grief has increased.Objective: Here, we review how bereavement-related psychological distress, including treating depression secondary to bereavement, has been addressed pharmacologically and the efficacy of these treatments.Methods: Included studies focused on (1) patients bereaved by any cause, (2) patients suffering from bereavement-related mental health problems, and (3) pharmacotherapy interventions to treat those bereavement-related mental health problems. Six databases (MEDLINE, Embase, the Cochrane Library, APA PsycInfo, Scopus, and Web of Science) were searched on 1 October 2020, and updated through 18 December 2024. Studies were selected by two independent reviewers and data were extracted and analysed qualitatively and quantitatively, with meta-analysis performed to calculate standardized mean differences (SMD) of treatment effects. Bias was assessed using the NIH Study Quality Assessment Tools.Results: Thirty-three studies (10 case series/studies, 7 cohort studies, 16 clinical trials) comprising 211,920 participants met eligibility criteria. Of nine medication classes represented, antidepressants were most commonly studied. No medications reduced grief symptomatology across any controlled studies; antidepressants and a beta blocker plus aspirin intervention appeared efficacious for depression symptomatology in bereaved individuals. SMD of effect of pharmacologic intervention on grief over control was negligible (-0.06 [95% CI, -0.31-0.19], data from three studies); SMD of effect of pharmacologic intervention on depression over control was small and not significant (-0.29 [95% CI, -0.68-0.10], data from two studies). Overall, study quality was low.Conclusions: Weak methodology and inconsistent data reporting presented challenges to synthesizing results. There is no evidence to support the use of current pharmacologic treatment for prolonged grief disorder, highlighting the need for further research to fill this gap in treatment options.
Related
- Interventions to reduce diabetes-related distress among adults with type 1 or type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
- Pain‐Related Outcome Domains and Measures in Randomized Controlled Trials of Treatment for Acute Abdominal Pain: A Systematic Review
- Pharmacological treatment of patent ductus arteriosus: lessons from recent randomized trials.
- Assessing fertility-related quality of life and psychological distress among infertile women: A cross-sectional study
- Symptom burden, Psychosocial Distress, Resilience and Health-Related Quality of Life in Women with Metastatic Breast Cancer Receiving Contemporary Systemic Therapy
BibTeX
@article{laplante2026pharmacological,
title = {{Pharmacological treatment of bereavement-related distress: a systematic review.}},
author = {Charlotte D LaPlante and Sydney C Saviano and Madeleine M Hardt and Kevin Pain and Sindhu Kolla and Courtney Lee and Paul K Maciejewski and David Russell and Geert E Smid and Holly G Prigerson},
journal = {European journal of psychotraumatology},
year = {2026},
month = nov,
doi = {10.1080/20008066.2026.2748196},
url = {https://europepmc.org/article/MED/42969145},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Pharmacological treatment of bereavement-related distress: a systematic review.
AU - Charlotte D LaPlante
AU - Sydney C Saviano
AU - Madeleine M Hardt
AU - Kevin Pain
AU - Sindhu Kolla
AU - Courtney Lee
AU - Paul K Maciejewski
AU - David Russell
AU - Geert E Smid
AU - Holly G Prigerson
PY - 2026
DA - 2026/11/02
JO - European journal of psychotraumatology
DO - 10.1080/20008066.2026.2748196
UR - https://europepmc.org/article/MED/42969145
AB - Background: With the recent addition of prolonged grief disorder into diagnostic manuals both in the United States (i.e. DSM-5-TR) and internationally (i.e. ICD-11), interest in pharmacologic treatment for grief has increased.Objective: Here, we review how bereavement-related psychological distress, including treating depression secondary to bereavement, has been addressed pharmacologically and the efficacy of these treatments.Methods: Included studies focused on (1) patients bereaved by any cause, (2) patients suffering from bereavement-related mental health problems, and (3) pharmacotherapy interventions to treat those bereavement-related mental health problems. Six databases (MEDLINE, Embase, the Cochrane Library, APA PsycInfo, Scopus, and Web of Science) were searched on 1 October 2020, and updated through 18 December 2024. Studies were selected by two independent reviewers and data were extracted and analysed qualitatively and quantitatively, with meta-analysis performed to calculate standardized mean differences (SMD) of treatment effects. Bias was assessed using the NIH Study Quality Assessment Tools.Results: Thirty-three studies (10 case series/studies, 7 cohort studies, 16 clinical trials) comprising 211,920 participants met eligibility criteria. Of nine medication classes represented, antidepressants were most commonly studied. No medications reduced grief symptomatology across any controlled studies; antidepressants and a beta blocker plus aspirin intervention appeared efficacious for depression symptomatology in bereaved individuals. SMD of effect of pharmacologic intervention on grief over control was negligible (-0.06 [95% CI, -0.31-0.19], data from three studies); SMD of effect of pharmacologic intervention on depression over control was small and not significant (-0.29 [95% CI, -0.68-0.10], data from two studies). Overall, study quality was low.Conclusions: Weak methodology and inconsistent data reporting presented challenges to synthesizing results. There is no evidence to support the use of current pharmacologic treatment for prolonged grief disorder, highlighting the need for further research to fill this gap in treatment options.
SN - 2000-8066
ER -